• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
H1N1 Vaccines - Global Strategic Business Report Product Image

H1N1 Vaccines - Global Strategic Business Report

  • Published: August 2013
  • Region: Global
  • 125 Pages
  • Global Industry Analysts, Inc

This report analyzes the Global market for H1N1 Vaccines in US$ Million. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2018.

The report profiles 29 companies including many key and niche players such as:

- Abbott Laboratories
- Baxter International, Inc.
- CPL Biologicals Pvt. Ltd.
- CSL Limited
- bioCSL
- GlaxoSmithKline Plc
- MedImmune, LLC
- Novartis AG
- Sanofi Pasteur
- SA
- Sinovac Biotech Ltd.
- Zydus Cadila.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. Executive Summary
1. GLOBAL MARKET OVERVIEW
A Prelude
Current and Future Analysis
Challenges Facing Healthcare Industry in Tackling Pandemics
Cumbersome Production Process of Pandemic Vaccines
Inefficiencies in Vaccine Distribution: A Cause of Concern
Competitive Scenario
H1N1 Influenza Vaccines and Manufacturers

2. GROWTH DRIVERS & INHIBITORS
Key Growth Drivers
Emerging Economies Present Potent Markets for H1N1 Vaccines
Consumer Awareness About Influenza Vaccines on the Rise
Threat of Antigenic Shift of H1N1 Virus Lingers
Influenza A(H1N1) pdm09 Virus Continues to Influence Global Influenza Activity
Government Purchases Continue to Propel Sales
Table 1: Mortality Rates of Major Influenza Pandemics Over the Last 100 Years (includes corresponding Graph/Chart)
Key Growth Inhibitors
High Competition Lowers Profit Margins
Shorter Lifecycle Of Pandemic Influenza
Ongoing Financial Crisis Affects Drug Prices and Manufacturing Cycles
Large-Scale Investments Pose Entry Barriers for Smaller Players

3. AN INSIGHT INTO GLOBAL VACCINES MARKET
Vaccines Market to Witness Robust Increase in Sales Driven by Robust Demand
Pneumococcal and Pediatric Multivalent Vaccines Dominate Sales
Table 2: Global Vaccines Market by Category (2012): Percentage Breakdown of Value Sales for Pneumococcal, Pediatric Multivalent, HPV, Influenza, Hepatitis, Rotavirus, Adult Booster, Meningococcal and Shingles (includes corresponding Graph/Chart)
Competitive Scenario
Table 3: Global Vaccines Market by Leading Manufacturer (2012): Percentage Market Share Breakdown of Value Sales for Sanofi Pasteur, GlaxoSmithKline, Merck & Co, Pfizer, Novartis Vaccines & Diagnostics, Astra Zeneca and Others (includes corresponding Graph/Chart)
H1N1 Influenza Diagnostic Tests
Table 4: Global Laboratory Rapid Testing by Leading Players (2012): Percentage Market Share Breakdown of Value Sales for Alere, Quidel, Meridian Bioscience, Beckman Coulter/Danaher, OraSure and Others (includes corresponding Graph/Chart)
Major Trends
Antigenic Shift of Virus Unlocks Possibilities for New Seasonal Influenza Vaccines
Quadrivalent Vaccines - A Whole New Generation of Seasonal Influenza Vaccines
Innovations in Vaccine Technology to Drive the Effort for a Universal Influenza Vaccine

4. H1N1 PANDEMIC - A HISTORICAL PERSPECTIVE
Influenza A (H1N1) 2009: The Global Pandemic
Table 5: Global Death Toll from 2009 A H1N1 (2009-2012) (includes corresponding Graph/Chart)

5. ECONOMIC IMPACT OF H1N1 PANDEMIC IN RETROSPECT
Pork & Pork Products
Airlines, Tourism & Hospitality
Hand Sanitizers
Table 6: US Market Revenues for Hand-Sanitizers for the Years 2008 through 2012 in US$ Millions (includes corresponding Graph/Chart)
Healthcare & Pharmaceuticals

6. H1N1 INFLUENZA - AN OVERVIEW
Influenza Virus: A Quick Primer
Symptoms and Characteristics
Types of Influenza
Influenza A Virus
Influenza A (H1N1) Virus
Different Names, in Different Countries
Symptoms and Risk Factors
The Pandemic Life-Cycle
Seasonal Influenza vis-à-vis H1N1 Flu
How H1N1 Is Diagnosed?
Prevention and Vaccination Against H1N1
Prevention
Vaccination
Vaccine Virus Selection for the 2012-2013 Influenza Season
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern Hemisphere for 2013-2014
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere for 2013
How H1N1 Vaccine is Prepared?
Egg-Based Production Process
Cell Culture-Based Technology
Recombinant Technology
Side Effects of H1N1 Vaccine
Primary Targets for Vaccination
Adverse Group for Vaccination
Treatment for Swine-Flu Infected Individuals
Anti-Virals for Pandemic (H1N1) 2009 Infection
Recommended Dosage of Anti-Viral
Peramivir - An Investigational Antiviral for H1N1

7. REGULATORY APPROVALS
GSK Obtains Marketing Authorization for Quadrivalent Influenza Vaccine in the UK and Germany
Sanofi Pasteur's Review Application for Quadrivalent Influenza Vaccine Accepted by EU
MedImmune Announces FDA Clearance of First Quadrivalent Flu Vaccine
Novartis Announces FDA Approval for Cell-Culture Derived Vaccine
GlaxoSmithKline Obtains FDA Approval for FLUARIX® QUADRIVALENT
Tianyuan Receives GMP Certification for Influenza and H1N1 Vaccine
Kitasato Daiichi Sankyo Vaccine and Daiichi Sankyo Group Obtain Approval from Japanese Government for H1N1 Vaccine Production
Baxter Secures rMRP Approval from Austrian Agency for Health and Food Safety
AstraZeneca Announces European Commission's Approval of FLUENZ Vaccine

8. REGULATORY APPROVALS IN THE RECENT PAST
Serum Institute of India Secures Approval from DCGI for Usage of HIN1 Injectable Vaccine
Quest Diagnostics Obtains Approval for Simplexa Influenza A H1N1 Test from FDA
Zydus Cadila Obtains Approval from DCGI
Intelligent Medical Devices Receives FDA Approval for Usage of H1N1 Influenza Virus Assay
CSL Biotherapies Receives TGA Approval for Panvax® H1N1
WHO Prequalifies Arepanrix™ H1N1 Vaccine of GlaxoSmithKline
CSL Obtains Approval for Extended Use of 2009 HINI Influenza vaccine in Infants
Novartis Receives Approval for Celtura®
Baxter Obtains Approval for Vero Cell-Based CELVAPAN H1N1 Vaccine in Europe
CHMP Recommends Approval of Novartis Focetria® in Europe
Sanofi Pasteur Obtains License from the US FDA for Influenza A (H1N1) 2009 Monovalent Vaccine
Sanofi Pasteur Receives Approval for New Vaccine Production Facility
US FDA Approves Supplemental BLA of GSK, for Unadjuvanted Influenza A (H1N1) Pandemic Vaccine
Health Canada Approves H1N1 Virus Vaccine
Sanofi Pasteur Gains Approval of Afssaps for A (H1N1) 2009 Vaccine in France
Novartis Obtains Prequalification Status from the WHO for Supply of Influenza A (H1N1) 2009 Vaccines in Developing World
Novartis Obtains Swissmedic Approval for Celtura®
CSL Biotherapies Receives US FDA Licensure for its Thimerosal
free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine
MedImmune Receives US FDA Approval for Nasal Spray H1N1 Vaccine
Sinovac Obtains Revised Approval for PANFLU.1 (H1N1) from State Food and Drug Administration
Sinovac Gains Certificate of Approval for Supply of PANFLU.1 in Mexico
Jiangsu Yanshen Gains Manufacturing License from SFDA, for H1N1 Flu Vaccine

9. PRODUCT LAUNCHES
FGBU Federal Center Develops H1N1 Swine Flu Inactivated Vaccine
Biolab Launches New Diagnostic Test for Swine Flu
VABIOTECH Develops Vaccines for A/H1N1 and A/H5N1 Viruses
Focus Diagnostics and 3M Unveil Simplexa™ Test on 3M™ Integrated Cycler
Bharat Biotech Introduces HNVAC H1N1 Swine Flu Vaccine
Serum Institute Unveils Nasovac Nasal Vaccine
Zydus Cadila Rolls Out Vaxiflu-S H1N1 Vaccine
The Scientific Research Institute Introduces New A/H1N1 Flu Vaccine

10. RECENT INDUSTRY ACTIVITY
bioCSL Restarts Manufacture of Influenza Vaccine
bioCSL Obtains Government Contracts for Vaccine Distribution
InGen Biosciences Inks Exclusive Dual Partnership Agreements
Vical and U.S. Naval Medical Research Center Extend Collaboration
Seegene and H1N1 Cross-Agencies Task Force Sign Research Agreement

11. INDUSTRY ACTIVITIES IN THE RECENT PAST
Vical and GenomIdea Ink Evaluation and Supply Agreement
Sinovac Biotech Signs Exclusive Distribution and Supply Licensing Agreement with Parenteral Biotech
Biological E Obtains License from VaxInnate for H1N1 Pandemic Swine Flu Vaccine
Fraunhofer USA Initiates Human Trial of H1N1 Influenza Vaccine
Novavax Announces Positive Results of A/H1N1 Pandemic Influenza Vaccine
Sinovac Biotech Clinches Fifth Consecutive Supply Order from MIIT for Panflu.1 H1N1 Vaccine
Zydus Cadila Completes Phase I Clinical Trial With its H1N1 Vaccine
Cadila Pharmaceuticals and Novavax Launch CPL Biologicals Pvt. Ltd.
Novartis Delivers 7.5 Million Doses of Influenza A (H1N1) Vaccine to HHS
Novartis Opens New Production Facility for Cell Culture-Based Influenza Vaccines Production in the United States
Novartis to Takeover Majority Interest in Chinese H1N1 Vaccine Maker
PhageVax Launches DNA Vaccine Platform
NIH to Initiate 2009 H1N1 Influenza Vaccine Trial in Persons with Asthma
Inovio Teams Up with Canadian Health Agency Pennsylvanian University on Swine Flu Vaccine
Simcere to Acquire Majority Interest in ChinaVax
Sanofi Pasteur Clinches Additional Order from HHS Department of the US
Sanofi Pasteur Bags Order from French Health Ministry, for Influenza A (H1N1) Vaccine
Sanofi Pasteur Inks Deal with Butantan Institute for Supply of Influenza A (H1N1) Virus Vaccine
McKesson Extends Partnership Deal with CDC
BD Receives Order from the Department of HHS
GSK Receives Order from the Department of HHS
MedImmune Recalls 4.7 Million Courses of Nasal H1N1 Flu Vaccine
Novavax and Xcellerex Enter into a Partnership

12. FOCUS ON SELECT GLOBAL PLAYERS
Abbott Laboratories (US)
Baxter International, Inc. (US)
CPL Biologicals Pvt. Ltd (India)
CSL Limited (Australia)
bioCSL (Australia)
GlaxoSmithKline Plc. (UK)
MedImmune, LLC. (USA)
Novartis AG (Switzerland)
Sanofi Pasteur, SA (France)
Sinovac Biotech Ltd. (China)
Zydus Cadila (India)

13. GLOBAL MARKET PERSPECTIVE
Table 7: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - North America, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2018 (includes corresponding Graph/Chart)
Table 8: World 10-year Analysis for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for North America, Europe, Asia-Pacific, and Rest of World Markets for the Years 2009, 2013 and 2018 (includes corresponding Graph/Chart)

III. MARKET

1. NORTH AMERICA
A.Market Analysis
Medicare and Medicaid Services for Influenza in the US
Table 9: CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2013-2014
Table 10: CDC Price List for Adult Influenza Vaccines in Basic Package: 2013-2014
Rapid Spread of the H1N1 Pandemic Pegged to Delay in Vaccine Administration
Swine Flu Pandemic Undermines US Pork Exports Considerably
Restrictions Imposed on Various Pork Products in Russia and China during Pandemic A H1N1Outbreak
Table 11: US Pork Exports by Destination Country (2008 & 2013E): Percentage Breakdown of Export Value for Japan, Mexico, China & Hong Kong, Canada, Russia, and Others (includes corresponding Graph/Chart)
A Historical Perspective on the H1N1 Pandemic in North America
First Case of H1N1 Infection Reported in Mexico
Swine Flu Spreads to the United States
Canadian Government Launches H1N1 Mass Vaccination Campaign
Major H1N1 Vaccines Available in North American Marketplace
US FDA-Approved Influenza Vaccines with 2009 H1N1 Virus Strain Indicated for 2013-2014 Flu Season
US FDA-Approved Quadrivalent Vaccines Incorporating H1N1 Strain for Influenza Type A and B (2013)
Preparations Authorized by Health Canada for Influenza, including H1N1, in Canada (2013)
Product Approvals & Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 12: North American Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2018 (includes corresponding Graph/Chart)

2. EUROPE
A.Market Analysis
Insights into European Influenza Vaccination Scenario
Cell-based Vaccine Production Remains Nascent
Major Influenza Vaccines Available in European Union Member Countries
Major H1N1 Flu Vaccines Available in Select East European Markets
ECDC Proposes New Influenza Vaccination Strategy
Immunization of High-Risk Demographics
Protecting Children, Adolescents, and Young Adults
Stemming the Spread of Infection in Public Centers
EMA approval for Quadrivalent LAIVs Pending
Anticipated Enhancements in Influenza Vaccine Products
Historical Perspective on the H1N1 Pandemic in Europe
Product Approvals & Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 13: European Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2018 (includes corresponding Graph/Chart)

3. ASIA-PACIFIC
A.Market Analysis
Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific Markets
Historical Perspective on the Outbreak of H1N1 Pandemic in 2009 in Select Regions
Japan
South Korea
Taiwan
Malaysia
Philippines
New Zealand
India
China
Hong Kong
Singapore
Australia
Product Approvals & Launches
Strategic Corporate Developments
Select Players
B.Market Analytics
Table 14: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2018 (includes corresponding Graph/Chart)

4. REST OF THE WORLD
A.Market Analysis
Product Approvals & Launches
B.Market Analytics
Table 15: Rest of the World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 29 (including Divisions/Subsidiaries - 33)

The United States (11)
Canada (1)
Japan (2)
Europe (6)
- France (1)
- The United Kingdom (2)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (13)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos